Results 131 to 140 of about 152,178 (350)

Artificial intelligence strategies for predicting kinase inhibitor resistance: A comprehensive review of methods, challenges, and future perspectives

Journal of Intelligent Medicine, EarlyView.
Abstract Kinase inhibitors are essential in targeted cancer therapy, yet resistance often emerges through secondary mutations, activation of compensatory signaling pathways, or drug‐efflux mechanisms. Artificial intelligence (AI) provides a workflow‐based strategy rather than a list of unrelated tools for predicting and addressing kinase‐inhibitor ...
Faris Hassan, Mohanad Ali Deifallah, Alaa Zaghloul, Rania Elgohary   +3 more
wiley   +1 more source

Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment

Open Medicine, 2020
Trastuzumab, a humanized monoclonal antibody derived from recombinant DNA, is used in patients with breast cancer with HER2 gene amplification. The survival benefit from trastuzumab has been well established in patients with early and metastatic breast ...
Zhou Qiong, Dong Jie, Jiang Xiaodong, Pan Yueyin, Han Xinghua   +4 more
doaj   +1 more source

Recommendations for HER2 testing in the UK [PDF]

, 2000
Determining the HER2 status of breast carcinomas is a prerequisite for the use of the monoclonal antibody trastuzumab (Herceptin(R)), which has recently been licensed for the treatment of metastatic disease.
Bartlett, J., Cooke, T., Dowsett, M., Ellis, I.O., Gullick, W., Gusterson, B., Lee, P.B., Mallon, E., Walker, R.   +8 more
core   +2 more sources

Response of Brain and Meningeal Metastases to Trastuzumab-Deruxtecan in a Patient with HER2-Low Breast Cancer: A Case Report

, 2023
Benita Wolf, Vincent Dunet, Estelle Dubruc, Ana Dolcan, Marie Nicod Lalonde, Luis Schiappacasse, Khalil Zaman   +6 more
openalex   +1 more source

Changing Practices in Axillary Surgery After Neoadjuvant Breast Cancer Therapy: Insights From the EUSOMA European Database

Journal of Surgical Oncology, EarlyView.
ABSTRACT Introduction Sentinel lymph node biopsy (SLNB) after neoadjuvant treatment (NAT) is an increasing option for axillary surgery in patients responding to treatment, whether diagnosed as clinically node‐negative (cN0) or node‐positive (cN + ). This study evaluates SLNB trends in patients with NAT in a large European population.
Antonio J. Esgueva, Mariano Tomatis, Antonio Ponti, Lorenza Marotti, Maria Joao Cardoso, Kwok Leung Cheung, Jakob De Vries, Peter van Dam, Isabel T. Rubio, The Eusoma Working group, Chiara Annunziata Pasqualina Anghelone, Antonella Baldissera, Elisabetta Benozzi, Martine Berlière, Marina Bortul, Barbara Bussels, Francesco Caruso, Carla Cedolini, Fabio Corsi, Evelyn Despierre, Boudewijn Dullens, Gianluca Fogazzi, Lucio Fortunato, José Luis Fougo, Gianluca Frisoni, Daniele Generali, Alessandra Gennari, Matteo Ghilli, Marco Golinelli, Pedro Gouveia, Simona Grossi, Ruth Helfgott, Alessandra Huscher, Karolina F. Larsson, Sophie Marquette, Carmela Mocerino, Ida Negreiros, Francesca Pellini, Federico Piacentini, Romano Polato, Annemie Prové, Karol Rogowski, Giovanna Romanucci, Lorenzo Rossi, Claudia Francesca Rossi, Margherita Serra, Gracienne Staelens, Maud Vassilieff, Paolo Veronesi, Daniele Zanoni   +49 more
wiley   +1 more source

Improving HER2 Diagnostics with Digital Real‐Time PCR for Ultrafast, Precise Prediction of Anti‐HER2 Therapy Response in Patients with Breast Cancer

Small Methods, EarlyView.
This study presents a novel, clinically feasible HER2 testing method using a fully automated digital real‐time PCR platform. It enables real‐time absolute quantification of ERBB2 copy number alterations for rapid, simple, and accurate assessment of HEgR2 status, thereby overcoming the limitations of conventional testing and improving prediction of anti‐
Hee‐Joo Choi, Soo Young Park, Minsik Song, Jinhyuk Chang, YoonSik Kim, Hosub Park, Chihwan David Cha, Sohyeon Yang, Nam Hun Heo, Min Ji Song, Da Sol Kim, Hayeon Kim, Minuk Kim, Jae Eun Park, Yesung Lee, EunChae Ji, Heekyoung Chung, Ilecheon Jeong, Mineui Hong, Jin‐Wu Nam, Mee‐Hye Oh, Ji‐Hye Lee, Jinwoo Seol, Hee‐Young Won, Hyun‐Woo Song, Jaewon Eom, Do Young Lee, Han Suk Ryu, Si‐Hyong Jang, Jeong‐Yeon Lee   +29 more
wiley   +1 more source

MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6

Cellular Physiology and Biochemistry, 2017
Background/Aims: Trastuzumab is an important treatment used for patients with Her-2-positive breast cancer, but an increasing incidence of trastuzumab resistance has been observed clinically during the past decade.
Xiangdong Lu, Jingjing Ma, Jiahui Chu, Qing Shao, Yao Zhang, Guangping Lu, Jun Li, Xiang Huang, Wei Li, Yongfei Li, Yang Ling, Tao Zhao   +11 more
doaj   +1 more source

Male breast cancer [PDF]

, 2017
Male breast cancer (MBC) is a rare disease representing less than 1% of all breast cancers (BC) and less than 1% of cancers in men. Age at presentation is mostly in the late 60s.
A Bjørnerem, A Holleb, A Jemal, AC Antoniou, AM Shaaban, B D'Avanzo, Breast Cancer Linkage Consortium, C Gómez-Raposo, C Martinez-Bouzas, C Rudlowski, D Albo, D Ly, D Palli, DA Rigoni-Stern, DG Evans, DS Popovic, E Kreiter, EF Lewison, G Masci, G Ribeiro, GR Brown, I Ganly, I Sosnovskikh, I Zanna, IS Fentiman, IS Fentinam, J Boyd, J White, JD Fackenthal, JH Breasted, JL Gnerlich, JR Weiss, K Coard, K Syrjakoski, KA Johansen Taber, KD Crew, L France, L Ottini, L Ottini, LA Brinton, LA Brinton, LA Brinton, LA Brinton, LA Brinton, LA Korde, M Falchetti, M Golshan, MA Adank, MB Cook, ME Meijer-van Gelder, MM Munoz de Toro, MT Vietri, N Orr, N Rahman, O Gentilini, P Karamanakos, RM Ferzoco, S Paik, S Peng, S Shak, S Thorlacious, SH Giordano, SH Giordano, SH Giordano, T Grenader, V Silvestri, V Silvestri, V Speirs, WF Anderson, WF Anderson, Y Ge, ZI Mitri   +71 more
core   +1 more source

Recent Advances in Bioconjugation of Aromatic Amino Acid Residues by a Reactivity‐Guided Approach

The Chemical Record, EarlyView.
This review highlights recent advances in the bioconjugation of aromatic amino acids residues, focusing on strategies that leverage their inherent chemical reactivity to enable precise and versatile modifications of biomacromolecules, illustrating relevant applications.
Bruno M. da S. Santos, Lívia C. R. M. da Frota, Thais G. Silva, Fernanda G. Finelli   +3 more
wiley   +1 more source

EPMA position paper in cancer:current overview and future perspectives [PDF]

, 2015
At present, a radical shift in cancer treatment is occurring in terms of predictive, preventive, and personalized medicine (PPPM). Individual patients will participate in more aspects of their healthcare.
Bubnov, Rostylav, Danesi, Romano, Desiderio, Dominic M., Grech, Godfrey, Hagan, Suzanne, Vittadini, Giorgio, Yoo, Byong Chul, Zhan, Xianquan   +7 more
core   +5 more sources